• 諮詢熱線+852 3480 8393

Logo
  • 首頁
  • 公司介紹
    • 背景
    • 免疫治療日本
    • 免疫治療香港
    • 腫瘤科醫生
  • 免疫細胞治療
    • 免疫細胞治療/自體免疫療法
    • 樹突狀細胞/DC疫苗療法
    • 自然殺傷細胞/NK細胞療法
    • 淋巴因子活化殺傷細胞(殺手T細胞)療法
    • 免疫治療成功率
    • 免疫治療副作用
    • 免疫治療費用
  • 醫生介紹
    • 日本
  • 治療成果
  • 癌症預防/防復發
    • 癌症復發率
    • 癌症預防
  • 最新資訊
    • 新聞
    • 臨床醫學報告
  • 聯絡我們

最新資訊

  • 首頁
  • 最新資訊
  • 臨床醫學報告
首頁 > 最新資訊 > 臨床醫學報告 > Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses

Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses

  • Cell Mol Immunol
  • 2022-06-17
  • 0 次瀏覽

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264306/


Abstract

Dendritic cells are powerful antigen-presenting cells that are essential for the priming of T cell responses. In addition to providing T-cell-receptor ligands and co-stimulatory molecules for naive T cell activation and expansion, dendritic cells are thought to also provide signals for the differentiation of CD4+ T cells into effector T cell populations. The mechanisms by which dendritic cells are able to adapt and respond to the great variety of infectious stimuli they are confronted with, and prime an appropriate CD4+ T cell response, are only partly understood. It is known that in the steady-state dendritic cells are highly heterogenous both in phenotype and transcriptional profile, and that this variability is dependent on developmental lineage, maturation stage, and the tissue environment in which dendritic cells are located. Exposure to infectious agents interfaces with this pre-existing heterogeneity by providing ligands for pattern-recognition and toll-like receptors that are variably expressed on different dendritic cell subsets, and elicit production of cytokines and chemokines to support innate cell activation and drive T cell differentiation. Here we review current information on dendritic cell biology, their heterogeneity, and the properties of different dendritic cell subsets. We then consider the signals required for the development of different types of Th immune responses, and the cellular and molecular evidence implicating different subsets of dendritic cells in providing such signals. We outline how dendritic cell subsets tailor their response according to the infectious agent, and how such transcriptional plasticity enables them to drive different types of immune responses.

Source: Hilligan, Kerry L, and Franca Ronchese. “Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses.” Cellular & molecular immunology vol. 17,6 (2020): 587-599. doi:10.1038/s41423-020-0465-0


上一篇:Dendritic Cell–Based Immunotherapy: State of the Art and Beyond 下一篇:Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment

欄目分類

  • 新聞 16
  • 臨床醫學報告 13

最新文章

  • Targeting dendritic cells in pancreatic ductal adenocarcinoma
    2022-06-17
  • Modified Immunotherapy Approach Shows Promise for Leukemia Subscribe
    2022-06-17
  • Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
    2022-06-17
  • WT1 (Wilms' Tumor Gene 1): Biology and Cancer Immunotherapy
    2022-06-17
  • NK cell-based cancer immunotherapy: from basic biology to clinical development
    2022-06-17
  • Targeted Cancer Therapy by Dendritic Cell Vaccine
    2022-06-17
  • Enhancing Dendritic Cell Therapy in Solid Tumors with Immunomodulating Conventional Treatment
    2022-06-17
  • Antigen presentation by dendritic cells and their instruction of CD4+ T helper cell responses
    2022-06-17
  • Dendritic Cell–Based Immunotherapy: State of the Art and Beyond
    2022-06-17
  • Review of Dendritic Cells, Their Role in Clinical Immunology, and Distribution in Various Animal Species
    2022-06-17
  • Improved survival ratios correlate with myeloid dendritic cell restoration in acute-on-chronic liver failure patients receiving methylprednisolone therapy
    2022-05-05
  • Effect of cytokine‑induced killer cells combined with dendritic cells on the survival rate and expression of 14‑3‑3ζ and p‑Bad proteins in Lewis lung cancer cell lines
    2022-05-05
  • Cancer immunotherapy via dendritic cells
    2022-05-05
所有文章
Logo
  • 郵箱:info@asiaimmune.com
  • 電話:+852 3480 8393
  • 微信:aicl_hk

免疫細胞治療

  • 免疫細胞治療/自體免疫療法
  • 樹突狀細胞/DC疫苗療法
  • 自然殺傷細胞/NK細胞療法
  • 淋巴因子活化殺傷細胞(殺手T細胞)療法
  • 免疫治療成功率
  • 免疫治療副作用
  • 免疫治療費用

公司地址

  • 九龍尖沙咀漢口道28號亞太中心8樓812室
  • +852 3480 8393

Copyright © 2022. Designed by Asia Immunotherapy Company Limited.